Experienced in Superficial Thrombophlebitis

Roel W. Van Kampen

Sittard, LI, NL 
Experienced in Superficial Thrombophlebitis
Sittard, LI, NL 
OverviewLocationsClinical Research

Overview

Roel Van Kampen practices in Sittard, Netherlands. Mr. Van Kampen is rated as an Experienced expert by MediFind in the treatment of Superficial Thrombophlebitis. His top areas of expertise are Superficial Thrombophlebitis, Multiple Myeloma, Small Lymphocytic Lymphoma (SLL), and Chronic Lymphocytic Leukemia (CLL).

His clinical research consists of co-authoring 34 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Superficial Thrombophlebitis.

Gender
Male

Locations

Sittard, LI, Netherlands
Other Locations
Tergooi Ziekenhuis
Hilversum, NH, Netherlands
Geleen, LI, Netherlands
Heerlen, LI, Netherlands
Maastricht, LI 6202AZ, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drugs: R-CHOP, R-CHOP/R-HAD, Rituximab, Lenalidomide
Study Phase: Phase 3

34 Total Publications

Frail subgroups determine heterogeneous outcomes in older patients with NDMM - long-term follow-up of the HOVON 143 trial.
Frail subgroups determine heterogeneous outcomes in older patients with NDMM - long-term follow-up of the HOVON 143 trial.
Journal: Blood advances
Published: June 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Van Kampen's expertise for a condition
ConditionClose
        View All 13 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile